Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other financing activities: 2018-2021

Historic Other financing activities for ImmunityBio (IBRX) over the last 2 years, with Sep 2021 value amounting to -$1.2 million.

  • ImmunityBio's Other financing activities fell 629.45% to -$1.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 million, marking a year-over-year increase of 2087.88%. This contributed to the annual value of $1.4 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ImmunityBio reported Other financing activities of -$1.2 million as of Q3 2021, which was down 145.31% from $2.6 million recorded in Q1 2021.
  • ImmunityBio's 5-year Other financing activities high stood at $2.6 million for Q1 2021, and its period low was -$1.2 million during Q3 2021.
  • Over the past 3 years, ImmunityBio's median Other financing activities value was $33,000 (recorded in 2019), while the average stood at $179,375.
  • Over the last 5 years, ImmunityBio's Other financing activities had its largest YoY gain of 2,033.33% in 2021, and its largest YoY loss of 629.45% in 2021.
  • ImmunityBio's Other financing activities (Quarterly) stood at $73,000 in 2018, then plummeted by 64.38% to -$66,000 in 2019, then plummeted by 507.50% to -$163,000 in 2020, then crashed by 629.45% to -$1.2 million in 2021.
  • Its Other financing activities was -$1.2 million in Q3 2021, compared to $2.6 million in Q1 2021 and -$163,000 in Q3 2020.